Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
"Chemo-Switch" Regimen in Advanced Melanoma
NCT00673361Phase 2Terminated
- Sponsor
- Duke University
- Start
- Mar 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of sorafenib in melanoma, sponsored by Duke University. Primary endpoint: Progression-Free Survival at 24 weeks. Started Mar 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00673361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673361.